Your AI-Trained Oncology Knowledge Connection!

Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies : Episode 14

Opinion

Video

February 18, 2025

Logistical Considerations for Delivering TCR Therapy to Patients

A panelist discusses how the logistical challenges of delivering T-cell receptor (TCR) therapy include coordinating lymphodepletion timing, managing the multiweek manufacturing process, ensuring proper handling and chain of custody of cellular products, and requiring specialized treatment centers with cell therapy expertise and infrastructure.

EP: 1.Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis

EP: 2.Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel

EP: 3.SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety

EP: 4.Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies

EP: 5.Key Differences in T-Cell Response Therapy vs CAR T Therapy

EP: 6.Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey

EP: 7.Sequencing Strategies of Afami-Cel With Chemotherapy and Targeted Therapies

EP: 8.Addressing Potential Barriers to the Adoption of Afami-Cel Therapy

EP: 9.Best Practices for HLA and MAGE-A4 Testing

EP: 10.Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing

EP: 11.Approaches to First-Line Treatment for Synovial Sarcoma

EP: 12.Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases

EP: 13.Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

Now Viewing

EP: 14.Logistical Considerations for Delivering TCR Therapy to Patients

EP: 15.Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options

EP: 16.Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors

Video content above is prompted by the following:

What are the logistical challenges of delivering TCR therapy to patients?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest Conference Coverage

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512